ALB and liver disorder: Original observations reported in our study include the comparative evaluation of HCC risk after a balanced match between DAA-treated and untreated participants by propensity analysis according to demographic and virological data (age, sex, genotype HCV-3), as well as clinical variables serving as surrogate markers of liver function (bilirubin, platelet count, albumin, INR, creatinine and a history of previous decompensation), which are used in order to evaluate the effect of viral eradication and liver disease stage on the risk of HCC occurrence.